References
- United States General Accounting Office. Prescription Drugs: State Monitoring Programs May Help to Reduce Illegal Diversion. Hearings Before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives. March 4, 2004, Report #GAO-04–524T
- Alliance of States with Prescription Monitoring Programs. The goals of prescription monitoring, Available at http://www.nascsa.org/alliance/Goals.pdf. Accessed January 28, 2005.
- Institute of Medicine Committee on Care at the End of Life. Approaching death: Improving care at the end of life. National Academy Press, Washington, DC 1997
- Kaufman M. DEA withdraws its support of guidelines on painkillers. The Washington Post, Available at http://www.washingtonpost.com/wp-dyn/articles/ Accessed October 24, 2004.
- The American Alliance of Cancer Pain Initiatives. Statement on State Prescription Monitoring Programs. July, 2002
- American Cancer Society. Position Statement on Regulatory Barriers to Quality Cancer Pain Management. October, 2001
- Joranson D E, Carrow G M, Ryan K M, et al. Pain management and prescription monitoring. J Pain Symptom Manage 2002; 23(3)231–238
- Advisory Committee Meeting. Department of Health Professions, Prescription Monitoring Program Workplan. Roanoke, VA December 10, 2003
- Virginia Department of Health Professions. Virginia prescription monitoring program, Available at http://www.dhp.state.va.us/dhp-programs/pmp/default. Accessed October 24, 2004
- Virginia Department of Health Professions, Title of Regulations: 18 VAC 76–20–10 et seq. Statutory Authority: § 54.1–2505 and § 54.1-2520 of the Code of Virginia.
- Virginia Department of Health Professions. Virginia prescription monitoring program: Description of program, Available at http://www.dhp.state.va.us/dhp_. Accessed February 3, 2005.
- Bureau of Justice Assistance. Harold Rogers prescription monitoring program, Available at http://www.ojp.usdoj.gov/BJA/grant/prescripdrugs. Accessed October 24, 2004.
- Department of Health Professions Advisory Committee Meeting. Prescription Monitoring Program, Roanoke, VA, December 10, 2003
- Sigler K A, Guernsey B G, Ingrim N B, et al. Effect of a triplicate prescription law on prescribing of schedule II drugs. Am JHosp Pharm 1984; 41: 108–111
- Berina L F, Guernsey B G, Hokanson J A, Doutre W H, Fuller L E. Physician perception of a triplicate prescription law. Am J Hosp Pharm 1985; 42: 857–859
- Weintraub M, Singh S, Byrne L, Maharaj K., Guttmacher L. Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations. JAMA 1991; 266(17)2392–2397
- National Institute on Drug Abuse. Impact of Prescription Drug Diversion Control Systems on Medical Practice and Patient Care. NIDA Research Monograph 131, Rockville, MD 1993
- Wastila L J. The influence of multiple copy prescription programs (MCPPs) on analgesic utilization. J Pharm Care Pain Symptom Control 1996; 4(3)3–19